Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multicenter, single-group study designed to determine the effectiveness of Mucinex® when used by patients to treat SCB over a 12-week period, following a 2-week run-in period of no treatment (to establish a baseline).


Clinical Trial Description

Data will be collected via the Vitaccess Real[TM] platform from adult patients with SCB and HCPs based in the US. During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily and complete weekly bespoke surveys and the CASA-Q instrument. Patient-reported data will include prior usage of Mucinex®, treatment compliance, treatment satisfaction, and symptoms. During this same period of time, HCPs will report treatment satisfaction via electronic case report forms (eCRFs), and will also have the ability to spontaneously report any treatment-emergent adverse events. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05843669
Study type Interventional
Source American Health Research
Contact Selwyn Spangenthal, MD
Phone 704-926-8041
Email sspangenthal@charlottelung.com
Status Recruiting
Phase Phase 4
Start date July 6, 2023
Completion date May 1, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05533931 - Resistive Breathing Versus Inspiratory Hold Technique in Patients With Chronic Bronchitis N/A
Completed NCT01420445 - Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis Phase 2
Completed NCT01071161 - The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough Phase 3
Terminated NCT00524095 - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis Phase 2
Completed NCT00903955 - Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease N/A
Completed NCT00129883 - Adherence to Guidelines for Antibiotic Use in Respiratory Infections at Hospitals N/A
Recruiting NCT05075083 - Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD Phase 4
Recruiting NCT05075057 - Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD Phase 4
Terminated NCT02838108 - The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
Completed NCT02128529 - Epidemiology of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease (COPD) N/A
Completed NCT00298389 - Macrophage Phagocytosis in COPD
Withdrawn NCT00298402 - Macrophages in Smokers' Lung N/A
Terminated NCT00132951 - KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections Phase 4
Active, not recruiting NCT01969344 - Study of COPD Subgroups and Biomarkers
Completed NCT00680056 - Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients Phase 4
Completed NCT00106080 - Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD) N/A
Completed NCT00042718 - A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis. Phase 3
Completed NCT02099799 - The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD N/A
Completed NCT00342030 - Dietary and Genetic Factors in Asthma & Chronic Bronchitis in a Cohort of Chinese Singaporeans N/A
Withdrawn NCT02341183 - Novel Therapies for Muco-Obstructive Lung Diseases: Testing the Transnasal Pulmonary Delivery Device in COPD/CB Subjects N/A